Shearman And Sterling

News November 04, 2021

Orphazyme A/S’s Up To $50 Million At-The-Market Program

Shearman & Sterling represented Cowen and Company, LLC as sales agent in connection with the commencement of a U.S. at-the-market equity offering program by Orphazyme A/S to offer and sell American Depositary Shares having an aggregate offering price of up to $50 million.

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C.

The Team